Short answer
Teleflex Inc (TFX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1.
Teleflex Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026, with detailed figures in Exhibit 99.1
- Non-GAAP metrics emphasize pro forma revenue, constant-currency growth and adjusted diluted EPS
- Pro forma results incorporate the BIOTRONIK Vascular Intervention acquisition as if completed January 1, 2025
- Adjusted measures exclude restructuring, impairments, divestiture costs, amortization and Italian payback-related charges
- Investors should compare GAAP results with adjusted figures, given extensive exclusions affecting underlying performance assessment
Item 7.01 · Regulation FD Disclosure
- Slide presentation supports Teleflex’s November 5, 2026 conference call on third-quarter results
- Results cover the quarter ended September 30, 2026
- Investors should review Exhibit 99.2 for management’s financial and operating commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $567.8M, up 3.0% pro forma constant currency, with Vascular +4.6% and Surgical +5.1%
- Adjusted EPS $2.63 versus $1.89, while adjusted operating margin reached 25.0%
- 2026 adjusted EPS guidance raised to $7.50-$7.75, including $16.5M of IEEPA tariff refunds
- $350M share repurchases since July 1, covering 2.7M shares at $128.96 average; $400M remains authorized
- OEM sale generated $1.25B after-tax proceeds, supporting $700M debt repayment and revolving borrowings reduction; remaining divestiture targets year-end closing, potentially extending into 2027
Item EX-99.2 · Exhibit EX-99.2
- Q3 adjusted EPS $2.63, up 39.2% year over year, supported by higher margins, lower interest expense, fewer shares and tariff refunds
- OEM divestiture closed for $1.5B proceeds, $1.25B after tax, funding planned debt reduction and share repurchases
- Q3 pro forma constant-currency revenue grew 3.0%, with Vascular up 4.6%, Interventional up 0.2% and Surgical up 5.1%
- FY26 adjusted EPS guidance raised to $7.50-$7.75, while constant-currency revenue growth remains 3.5%-4.5%
- Capital return includes $1B buyback and ~$800M debt reduction, with $400M repurchase authorization remaining
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teleflex Inc 8-K filings
Get the next TFX 8-K as it lands
Follow TFX for push alerts, or ask the research agent what this filing means.